Supervivencia global y libre de progresión en pacientes con cáncer de mama sobre expresivo de HER 2 tratadas con quimioterapia durante el periodo 2009 2011 en el Instituto de Cáncer Solca de la ciudad de Loja

Abstract

Abstract:Background Breast cancer is one of the leading causes of mortality in women worldwide; in which HER2 overexpression occurs in 20-30%, appearing as an unfavorable prognostic factor in the overall survival of patients. Methods A descriptive study of the clinicopathological characteristics of patients with breast cancer of the Solca - Loja Institute, period 2009 - 2011, was carried out; 5-year overall survival was analyzed using the Kaplan-Meier methods comparing patients treated with chemotherapy plus trastuzumab (QT + T) versus patients treated with standard chemotherapy alone (QT). Results 124 cases were included; HER2 amplification took place in 29%. The average age at diagnosis was 49 years. The locally advanced disease was the most frequent (75%). Of the histological type, 88.89% was ductal. The 5-year survival was 64.3% (QT) and 59.1% (QT + T). Conclusion There is no difference in 5-year survival in patients with HER2 positive breast cancer with respect to the inclusion of monoclonal antibody treatment (trastuzumab)